Latest Capital Efficiency News

Opthea Limited resumes ASX trading as it pivots to develop OPT-302 for lymphangioleiomyomatosis, outlining a disciplined 18-month staged clinical program backed by A$31.2 million in cash.

Biome Australia has inked a binding deal with Specialty Probiotics Australia to shift its Activated Probiotics manufacturing onshore, aiming to boost gross margins above 65% and streamline working capital within 18 months.

Simble Solutions has launched a strategic collaboration with Macquarie University to accelerate development of its exclusive zinc oxide nanosensor technology, targeting e-skin applications and integration into its IoT platforms.

Desert Metals Limited has raised $1 million through a placement at a 2.9% premium, backing exploration at its Scotty Lithium and Monger Gold projects alongside new growth opportunities.

Black Bear Minerals has engaged Ausenco for detailed restart studies at its Shafter Silver Project, while securing a non-binding financing support letter from Export Finance Australia to explore funding pathways aligned with U.S.-Australia critical minerals priorities.

4DMedical has leapfrogged into the European lung health market by acquiring Austrian AI imaging firm contextflow, gaining immediate commercial presence and a CE-marked lung cancer screening solution.

Imugene has dosed the first patient in a new cohort combining its azer-cel CAR T therapy with BTK inhibitors, targeting patients with B-cell malignancies who failed prior BTKi treatment. This move broadens the trial’s scope and tackles a significant unmet need in blood cancer therapy.

Finder Energy is pushing ahead with its Kuda Tasi and Jahal (KTJ) oil development, lodging key regulatory approvals and progressing debt financing amid a firmer Brent oil price outlook. The company targets final investment decision by mid-2026 and aims for first oil in late 2027 or early 2028.

International Graphite Limited and Italian chemical producer Alkeemia have formalised a joint venture to develop a major graphite processing facility in Porto Marghera, Italy, targeting 15,000 tonnes per year by 2029 with first production expected in 2027.

Neurizon Therapeutics has boosted the participant count in its HEALEY ALS Platform Trial Regimen I from 160 to 240, capitalising on faster enrolment and philanthropic support to maintain costs and accelerate topline results to early Q3 2027.

VRX Silica’s updated 2026 Bankable Feasibility Study for Arrowsmith North confirms robust economics with an ungeared NPV8 of A$179.2 million and binding offtake contracts securing nearly 1 million tonnes annually.

Nufarm Limited posted a 35% rise in underlying net profit after tax to $52.1 million for HY26, driven by margin expansion and cost discipline despite a 5% revenue decline to $1.71 billion. The company confirmed its FY26 outlook, targeting strong earnings growth and leverage reduction.